Supplemental Online Content

Angelis A, Suarez Alonso C, Kyriopoulos I, Mossialos E. Funding sources of therapeutic and vaccine clinical trials for COVID-19 vs non–COVID-19 indications, 2020-2021. JAMA Netw Open. 2022;5(8):e2226892. doi:10.1001/jamanetworkopen.2022.26892

eFigure 1. Flow Diagram for the Identification of COVID-19 Therapeutics and Vaccines Clinical Trials
eFigure 2. Monthly Numbers of Therapeutics and Vaccines Clinical Trials and Their Funding Sources for COVID-19, Non-COVID-19, and Non-COVID-19 Infectious Disease Indications

This supplemental material has been provided by the authors to give readers additional information about their work.
eFigure 1: Flow diagram for the identification of COVID-19 therapeutics and vaccines clinical trials

Identification of COVID-19 therapeutics and vaccines clinical trials via ClinicalTrials.gov

Identification

Number of Phase 1 – Phase 3 clinical trials with a start date between January 1\textsuperscript{st} 2020 and August 31\textsuperscript{st} 2021:
\( n = 36,384 \)

Trials removed before screening:
- Trials not specifying “drug” or “biological” in “Intervention” (\( n = 21,113 \))
- Trials whose “Primary purpose” was specified as “diagnostic”, “basic science”, “screening”, device” (\( n = 997 \))

Screening

Trials screened (overall sample):
\( n = 14,274 \)

Trials not specifying “COVID” and/or “SARS-CoV2” in “Condition” (non-COVID-19 sample)
\( n = 12,297 \)

Included

Trials specifying “Infectious diseases” in “Report groups” “SARS-CoV2” in “Condition” (non-COVID-19 infectious disease sample)
\( n = 857 \)

Trials included for the analysis (COVID-19 sample)
\( n = 1,977 \)
eFigure 2: Monthly numbers of therapeutics and vaccines clinical trials and their funding sources for COVID-19 (a), non-COVID-19 (b) and non-COVID-19 infectious disease (c) indications.
Note: Clinical trials assigned a “not applicable” phase status were also included.